Evidence map›Paper›PMID 29653561›Full record

ArticleBMC cancer2018

Micro-RNA-186-5p inhibition attenuates proliferation, anchorage independent growth and invasion in metastatic prostate cancer cells.

Dominique Z Jones, M Lee Schmidt, Suman Suman, Katharine R Hobbing, Shirish S Barve, Leila Gobejishvili, Guy Brock, Carolyn M Klinge, Shesh N Rai, Jong Park and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. The Role of MiRNA in Cancer: Pathogenesis, Diagnosis, and Treatment.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Dominique Z JonesDepartment of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY, 40292, USA.
M Lee SchmidtDepartment of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY, 40292, USA.
Suman SumanDepartment of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY, 40292, USA.
Katharine R HobbingDepartment of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY, 40292, USA.
Shirish S BarveDepartment of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY, 40292, USA.
Leila GobejishviliDepartment of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY, 40292, USA.
Guy BrockDepartment of Biomedical Informatics, The Ohio State University, Columbus, USA.
Carolyn M KlingeJames Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, USA.
Shesh N RaiJames Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, USA.
Jong ParkDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA.
Geoffrey J ClarkDepartment of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY, 40292, USA.
Rajesh AgarwalDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Denver, USA.
LaCreis R KiddDepartment of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY, 40292, USA. lrkidd01@exchange.louisville.edu.
University of Louisville · USMoffitt Cancer Center · USThe Ohio State University · USUniversity of Colorado Denver · USUniversity of Montana · US

Funding

WKU Lead Faculty AwardP20GM103436 · NIGMS · UNIVERSITY OF LOUISVILLE · PI ERIC C ROUCHKA · 2012 to 2026
$60.1M
PILOT PROJECT PROGRAMP30GM106396 · NIGMS · UNIVERSITY OF LOUISVILLE · PI MILLER, DONALD M. · 2013 to 2017
$5.4M
University of Louisville Cancer Education ProgramR25CA134283 · NCI · UNIVERSITY OF LOUISVILLE · PI HEIN, DAVID W, KIDD, LA CREIS RENEE · 2011 to 2022
$3.1M
NCI NIH HHS R25 CA134283NCI NIH HHS R25CA134283NIGMS NIH HHS P20 GM103436NIGMS NIH HHS P20GM103436NIGMS NIH HHS P30 GM106396NIGMS NIH HHS P30GM106396
6 · The paper itself

Abstract

backgroundDysregulation of microRNA (miRNA) expression is associated with hallmarks of aggressive tumor phenotypes, e.g., enhanced cell growth, proliferation, invasion, and anchorage independent growth in prostate cancer (PCa).

methodsSerum-based miRNA profiling involved 15 men diagnosed with non-metastatic (stage I, III) and metastatic (stage IV) PCa and five age-matched disease-free men using miRNA arrays with select targets confirmed by quantitative real-time PCR (qRT-PCR). The effect of miR-186-5p inhibition or ectopic expression on cellular behavior of PCa cells (i.e., PC-3, MDA-PCa-2b, and LNCaP) involved the use bromodeoxyuridine (BrdU) incorporation, invasion, and colony formation assays. Assessment of the impact of miR-186-5p inhibition or overexpression on selected targets entailed microarray analysis, qRT-PCR, and/or western blots. Statistical evaluation used the modified t-test and ANOVA analysis.

resultsMiR-186-5p was upregulated in serum from PCa patients and metastatic PCa cell lines (i.e., PC-3, MDA-PCa-2b, LNCaP) compared to serum from disease-free individuals or a normal prostate epithelial cell line (RWPE1), respectively. Inhibition of miR-186-5p reduced cell proliferation, invasion, and anchorage-independent growth of PC-3 and/or MDA-PCa-2b PCa cells. AKAP12, a tumor suppressor target of miR-186-5p, was upregulated in PC-3 and MDA-PCa-2b cells transfected with a miR-186-5p inhibitor. Conversely, ectopic miR-186-5p expression in HEK 293 T cells decreased AKAP12 expression by 30%. Both pAKT and β-catenin levels were down-regulated in miR-186-5p inhibited PCa cells.

conclusionsOur findings suggest miR-186-5p plays an oncogenic role in PCa. Inhibition of miR-186-5p reduced PCa cell proliferation and invasion as well as increased AKAP12 expression. Future studies should explore whether miR-186-5p may serve as a candidate prognostic indicator and a therapeutic target for the treatment of aggressive prostate cancer.

Indexed as

A Kinase Anchor Proteinsbeta CateninCell Cycle ProteinsCell Line, TumorCell ProliferationCirculating MicroRNAGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMicroRNAsNeoplasm InvasivenessNeoplasm MetastasisNeoplasm StagingProstatic NeoplasmsProto-Oncogene Proteins c-aktAKAP12 protein, humanA Kinase Anchor Proteinsbeta CateninCell Cycle ProteinsCirculating MicroRNAMicroRNAsMIRN186 microRNA, humanProto-Oncogene Proteins c-aktAKAP12MetastasismicroRNAmiR-186Prostate cancerSerumβ-catenin

Identifiers

PMID29653561
PMCPMC5899400
OpenAlexW2801093221

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.